NCT02340936 - Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

February 20, 2019

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

LR-ESHAP (lenalidomide 5 mg)

3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

DRUG

LR-ESHAP (lenalidomide 10 mg)

3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

DRUG

LR-ESHAP (lenalidomide 15 mg)

3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

DRUG

LR-ESHAP (lenalidomide 20 mg)

3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.

Trial Locations (9)

Hospital Universitario 12 de Octubre, Madrid

Hospital Regional Universitario de Málaga, Málaga

Alejandro Martín, Salamanca

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitario La Fe, Valencia

ICO- Hospital Universitari Germans Trias i Pujol, Badalona

ICO- Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital del Mar, Barcelona

Hospital Clinic i Provincial de Barcelona, Barcelona